From The Eye Foundation, Coimbatore, India.
J Cataract Refract Surg. 2020 Mar;46(3):428-433. doi: 10.1097/j.jcrs.0000000000000073.
To evaluate the safety and efficacy of photorefractive intrastromal corneal crosslinking (PiXL) for the treatment of low myopia using the epithelium-on approach with supplemental oxygen.
The Eye Foundation, Coimbatore, India.
Prospective interventional case series.
Myopic nonectatic eyes underwent PiXL using the Mosaic system. Ultraviolet-A (UV-A) irradiation of 365 nm wavelength was delivered in an accelerated (30 mW/cm) pulsed approach to provide a total fluence of 15 J/cm. Supplemental oxygen (concentration greater than 95%) was provided to increase the efficacy of the epithelium-on approach during the UV-A irradiation. Efficacy was determined by improvement in mean refractive spherical equivalent (MRSE), uncorrected distance visual acuity (UDVA), and keratometric flattening. Safety was determined by loss of lines of corrected distance visual acuity, endothelial cell loss, and adverse events.
Fifty eyes of 26 patients with a mean age of 22.73 ± 3.74 years were included. A significant improvement in UDVA from baseline (logarithm of the minimum angle of resolution [logMAR] 0.63 ± 0.25) was noted at the 3-month (logMAR 0.08 ± 0.15) and 6-month (logMAR 0.13 ± 0.18) follow-up visits (P < .001). Significant keratometric flattening from baseline was noted at all follow-up visits (P < .001). No significant endothelial cell loss or adverse effects were noted. A significant correlation was noted between the change in MRSE and preoperative corneal biomechanics (deformation amplitude ratio, P = .029).
Transepithelial PiXL with supplemental oxygen might be a safe and effective approach for reduction of myopia. The change in MRSE and keratometric flattening was greater in comparison with earlier protocols, including the epithelium-off approach.
评估经上皮角膜交联(PiXL)治疗低度近视的安全性和有效性,采用上皮下氧合补充治疗方法。
印度哥印拜陀市眼基金会。
前瞻性干预性病例系列研究。
近视非扩张眼接受 Mosaic 系统的 PiXL 治疗。采用 365nm 波长的紫外线-A(UV-A)照射,以加速(30mW/cm)脉冲方式提供总辐照度 15J/cm。在 UV-A 照射期间,提供浓度大于 95%的补充氧气,以提高上皮下氧合治疗方法的效果。通过平均等效球镜(MRSE)、未矫正远视力(UDVA)和角膜屈光度变平的改善来确定疗效。通过矫正远视力损失线、内皮细胞损失和不良事件来确定安全性。
纳入 26 例 50 只眼患者,平均年龄 22.73±3.74 岁。在 3 个月(logMAR 0.08±0.15)和 6 个月(logMAR 0.13±0.18)随访时,UDVA 从基线显著改善(logMAR 0.63±0.25)(P<.001)。在所有随访时,角膜屈光度变平均有显著改善(P<.001)。无明显内皮细胞丢失或不良反应。MRSE 变化与术前角膜生物力学(变形幅度比,P=0.029)之间存在显著相关性。
上皮下氧合补充治疗经上皮角膜交联可能是一种安全有效的治疗近视方法。与早期的上皮下氧合补充治疗方案(包括上皮下治疗)相比,MRSE 和角膜屈光度变平的变化更大。